U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623135) titled 'Lumateperone for Late-Life Depression' on May 28.
Brief Summary: The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Treatment Resistant Depression (TRD)
Late Life Depress...